Search

Your search keyword '"Lok, Catherine"' showing total 159 results
Start Over Author "Lok, Catherine" Language english
159 results on '"Lok, Catherine"'

1. Elastic fiber alterations and calcifications in calcific uremic arteriolopathy

Author

Colboc, Hester, Moguelet, Philippe, Bazin, Dominique, Letavernier, Emmanuel, Sun, Chenyu, Chessel, Anatole, Carvalho, Priscille, Lok, Catherine, Dillies, Anne-Sophie, Chaby, Guillaume, Maillard, Hervé, Kottler, Diane, Goujon, Elisa, Jurus, Christine, Panaye, Marine, Tang, Ellie, Courville, Philippe, Boury, Antoine, Monfort, Jean-Benoit, Chasset, François, Senet, Patricia, and Schanne-Klein, Marie-Claire

Published
2023
Full Text
View/download PDF

2. Chemotherapy-induced leg ulcers: a case series.

Author

Rousselot, Marion, Mahé, Emmanuel, Senet, Patricia, Rousselot, Philippe, Baudot, Nathalie, Moawad, Sandra, Schoeffler, Amélie, Goujon, Elisa, Villemur, Béatrice, Lok, Catherine, Cuny, Jean-François, Guern, Aurore Le, Sigal, Michèle-Léa, and Tella, Emilie

Abstract

Objective: New therapeutic classes of chemotherapy, including tyrosine kinase inhibitors (TKIs), are being developed, leading to unexpected cutaneous side-effects. The aim was to analyse the development of leg ulcers (LUs) associated with chemotherapy to identify their characteristics and management. Method: A retrospective multicentre study was conducted across nine French dermatology departments and one haematology department. We collected information on cancer history, cofactors of LUs, and management and evolution of the LUs. Results: The study included 45 patients divided into three groups: hydroxyurea treatment; targeted therapies including TKIs; and taxane treatment. Certain factors were common for arteriovenous leg ulcers, especially advanced age, the frequency of vascular cofactors and the painful nature of the ulcer; however, significant differences were apparent. In particular, the delay between the introduction of chemotherapy and the beginning of the LU. The delay in appearance of the LU was shorter for patients in the taxanes and TKIs groups versus patients treated with hydroxyurea (hydroxyurea versus taxanes: p<0.0001; hydroxyurea versus TKIs: p=0.004). Following the appearance of the LU, treatment was normally stopped (88%), with cicatrisation (91%) occurring within a period of 4.6 months on average. These results confirm the known association of hydroxyurea and LUs; however, other chemotherapies, including targeted therapies and taxanes, appear to be involved. Conclusion: Prescribers should be made aware of skin side-effects of chemotherapies and the risk–benefit of discontinuing chemotherapy for ulcer healing should be raised. Closer monitoring to control identified cofactors of LUs is required in patients receiving this type of chemotherapy, especially if they have LU-predisposing factors. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

3. Nailfold dermoscopy predicts the absence of a capillaroscopy sclerodermic pattern: The multicentre, prospective VASCUL‐R trial.

Author

Monfort, Jean‐Benoît, Klejtman, Tiffany, Lazareth, Isabelle, Kottler, Diane, Blaise, Sophie, Imbert, Bernard, Chaby, Guillaume, Lok, Catherine, Maillard, Hervé, Beneton, Nathalie, Journet‐Tollhupp, Julie, Goujon, Elisa, Jacquin, Aurélien, Tella, Emilie, Mboup, Bassirou, Vicaut, Eric, and Senet, Patricia

Subjects
RAYNAUD'S disease, DERMOSCOPY, CAPILLAROSCOPY, DERMATOLOGISTS, HEMORRHAGE, CAPILLARIES
Abstract

Background: Nailfold capillaroscopy is recommended to diagnose primary or secondary Raynaud's phenomenon (RP). Capillaroscopy is normal in primary RP, which is the most frequent. Screening for RP capillary anomalies with nailfold dermoscopy has been promising. Objective: To determine whether normal nailfold dermoscopy—based on the absence of five criteria that define a sclerodermic pattern—is able to predict normal capillaroscopy with good positive‐predictive value (PPV). Methods: Prospective, 2‐phase (monocentre and multicentre) study on patients at first consultation for RP undergoing nailfold video capillaroscopy (NVC) and nailfold dermoscopy by two different 'blinded' trained observers, respectively, a vascular specialist and a dermatologist, not familiar with capillaroscopy. The five criteria noted were as follows: disorganization, megacapillaries, low capillary density, avascular areas and haemorrhages. Results: Based on 105 patients, the dermoscopy PPV for a normal NVC was 100% (p = 0.015), with 37.9% sensitivity, when no criterion was observed. Excluding haemorrhages, the PPV remained 100% (p < 0.0001), with sensitivity rising to 73.7% and 100% specificity. Conclusions: Normal nailfold dermoscopy with the absence of four easy‐to‐observe criteria predicts normal NVC with an excellent PPV. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. Adjuvant therapy with pegylated interferon-alfa2b vs observation in stage II B/C patients with ulcerated primary: Results of the European Organisation for Research and Treatment of Cancer 18081 randomised trial

Author

Eggermont, Alexander M.M., Rutkowski, Piotr, Dutriaux, Caroline, Hofman-Wellenhof, Rainer, Dziewulski, Peter, Marples, Maria, Grange, Floren, Lok, Catherine, Pennachioli, Elisabetta, Robert, Caroline, van Akkooi, Alexander C.J., Bastholt, Lars, Minisini, Alessandro, Marshall, Ernest, Salès, François, Grob, Jean-Jacques, Bechter, Oliver, Schadendorf, Dirk, Marreaud, Sandrine, Kicinski, Michal, Suciu, Stefan, and Testori, Alessandro A.E.

Published
2020
Full Text
View/download PDF

9. Clostridium difficile infection and immune checkpoint inhibitor–induced colitis in melanoma: 18 cases and a review of the literature

Author

Vuillamy, Chloé, Arnault, Jean-Philippe, Fumery, Mathurin, Mortier, Laurent, Monestier, Sandrine, Mansard, Sandrine, Bens, Guido, Duval-Modeste, Anne-Bénédicte, Funck-Brentano, Elisa, Jeudy, Géraldine, Machet, Laurent, Chaby, Guillaume, Dadban, Ali, Lok, Catherine, Université de Picardie Jules Verne (UPJV), CHU Amiens-Picardie, Périnatalité et Risques Toxiques - UMR INERIS_I 1 (PERITOX), Institut National de l'Environnement Industriel et des Risques (INERIS)-Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 (ONCO-THAI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Hôpital de la Timone [CHU - APHM] (TIMONE), CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand, Centre Hospitalier Régional d'Orléans (CHRO), Hôpital Charles Nicolle [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU), Hôpital Ambroise Paré [AP-HP], CHU Dijon, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Service de Dermatologie (CHU de Dijon), UMR 1253 IBrain Imagerie & Cerveau Equipe 3 'Imagerie, Biomarqueurs & Thérapie' (IBT), Imagerie et cerveau (iBrain - Inserm U1253 - UNIV Tours ), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Service de dermatologie [CHU d'Amiens-Picardie]

Subjects
[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

International audience; Immunotherapy has become the standard of care for several types of cancer, such as melanoma. However, it can induce toxicity, including immune checkpoint inhibitor-induced colitis (CIC). CIC shares several clinical, histological, biological, and therapeutic features with inflammatory bowel disease (IBD). Clostridium difficile infection (CDI) can complicate the evolution of IBD. We aimed to characterize the association between CDI and CIC in patients treated with anti-CTLA-4 and anti-PD-1 for melanoma. Patients from nine centers treated with anti-CTLA-4 and anti-PD-1 for melanoma and presenting with CDI from 2010 to 2021 were included in this retrospective cohort. The primary endpoint was the occurrence of CIC. The secondary endpoints were findings allowing us to characterize CDI. Eighteen patients were included. Eleven were treated with anti-PD-1, four with anti-CTLA-4, and three with anti-PD-1 in combination with anti-CTLA-4. Among the 18 patients, six had isolated CDI and 12 had CIC and CDI. Among these 12 patients, eight had CIC complicated by CDI, three had concurrent CIC and CDI, and one had CDI followed by CIC. CDI was fulminant in three patients. Endoscopic and histological features did not specifically differentiate CDI from CIC. Nine of 11 patients required immunosuppressive therapy when CDI was associated with CIC. In nine cases, immunotherapy was discontinued due to digestive toxicity. CDI can be isolated or can complicate or reveal CIC. CDI in patients treated with immunotherapy shares many characteristics with CDI complicating IBD. Stool tests for Clostridium difficile should be carried out for all patients with diarrhea who are being treated with immunotherapy.

Published
2023
Full Text
View/download PDF

14. A Comparison of Two Regimens of Topical Corticosteroids in the Treatment of Patients with Bullous Pemphigoid: A Multicenter Randomized Study

Author

Joly, Pascal, Roujeau, Jean-Claude, Benichou, Jacques, Delaporte, Emmanuel, D'Incan, Michel, Dreno, Brigitte, Bedane, Christophe, Sparsa, Agnes, Gorin, Isabelle, Picard, Catherine, Tancrede-Bohin, Emmanuelle, Sassolas, Bruno, Lok, Catherine, Guillaume, Jean-Claude, Doutre, Marie-Sylvie, Richard, Marie-Aleth, Caux, Frédéric, Prost, Catherine, Plantin, Patrice, Chosidow, Olivier, Pauwels, Christine, Maillard, Hervé, Saiag, Philippe, Descamps, Vincent, Chevrant-Breton, Jacqueline, Dereure, Olivier, Hellot, Marie-France, Esteve, Eric, and Bernard, Philippe

Published
2009
Full Text
View/download PDF

15. French recommendations for the management of systemic sclerosis

Author

Hachulla, Eric, Agard, Christian, Allanore, Yannick, Avouac, Jérôme, Bader-Meunier, Brigitte, Belot, Alexandre, Berezne, Alice, Bouthors, Anne-Sophie, Condette-Wojtasik, Geraldine, Constans, Joël, de Groote, Pascal, Diot, Elisabeth, Dumas, Florence, Jego, Patrick, Joly, Francisca, Launay, David, Le Guern, Veronique, Le Quintrec, Janine-Sophie, Lescaille, Géraldine, Meune, Christophe, Moulin, Bruno, Nguyen, Christelle, Omeish, Nadine, Pene, Frédéric, Richard, Marie-Aleth, Rochefort, Juliette, Roren, Alexandra, Sitbon, Olivier, Sobanski, Vincent, Truchetet, Marie-Elise, Mouthon, Luc, Bayen, Marc, Bergot, Emmanuel, Berthier, Sabine, Bosco, Julia, Bouhnik, Yoram, Chaigne, Benjamin, Cottin, Vincent, Crestani, Bruno, Deligny, Christophe, Descroix, Vianney, Farge, Dominique, Godard, Dominique, Granel, Brigitte, Guilpain, Philippe, Imbert, Bernard, Le Quellec, Alain, Lega, Christophe, Lok, Catherine, Maillard, Hélène, Martin, Thierry, Pugnet, Grégory, Queyrel, Viviane, Raffray, Loïc, Rilliard, Frédéric, Romier, Mélanie, Schuller, Laurence, Servettaz, Amélie, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Université de Lille, Institute for Translational Research in Inflammation - U 1286 (INFINITE (Ex-Liric)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre hospitalier universitaire de Nantes (CHU Nantes), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut Cochin (IC UM3 (UMR 8104 / U1016)), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service d'immuno-hématologie pédiatrique [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Hôpital Femme Mère Enfant [CHU - HCL] (HFME), Hospices Civils de Lyon (HCL), Centre Hospitalier Annecy-Genevois [Saint-Julien-en-Genevois], Hôpital Jeanne de Flandres, Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 (GRITA), Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), CHU Bordeaux [Bordeaux], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), CHU Pontchaillou [Rennes], Hôpital Beaujon [AP-HP], Centre de recherche sur l'Inflammation (CRI (UMR_S_1149 / ERL_8252 / U1149)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Service de médecine interne et centre de référence des maladies rares [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Centre d'Immunologie et des Maladies Infectieuses (CIMI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Hôpital Avicenne [AP-HP], CHU Strasbourg, CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôpital de la Timone [CHU - APHM] (TIMONE), Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), and Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)

Subjects
medicine.medical_specialty, Poor prognosis, Hypertension, Pulmonary, Scleroderma Renal Crisis, Aucun, Connective tissue, MESH: Skin Diseases, Favorable prognosis, Recommendations, Skin Diseases, Scleroderma, MESH: Scleroderma, Systemic, 03 medical and health sciences, 0302 clinical medicine, MESH: Skin, Fibrosis, medicine, Humans, Pharmacology (medical), 030212 general & internal medicine, Generalized Disease, Position Statement, skin and connective tissue diseases, Genetics (clinical), Skin, 030203 arthritis & rheumatology, Scleroderma, Systemic, MESH: Humans, integumentary system, MESH: Hypertension, Pulmonary, business.industry, Interstitial lung disease, General Medicine, medicine.disease, Dermatology, Treatment, medicine.anatomical_structure, [SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human genetics, Medicine, Systemic sclerosis, business, Lung Diseases, Interstitial, MESH: Lung Diseases, Interstitial
Abstract

Systemic sclerosis (SSc) is a generalized disease of the connective tissue, arterioles, and microvessels, characterized by the appearance of fibrosis and vascular obliteration. There are two main phenotypical forms of SSc: a diffuse cutaneous form that extends towards the proximal region of the limbs and/or torso, and a limited cutaneous form where the cutaneous sclerosis only affects the extremities of the limbs (without passing beyond the elbows and knees). There also exists in less than 10% of cases forms that never involve the skin. This is called SSc sine scleroderma. The prognosis depends essentially on the occurrence of visceral damage and more particularly interstitial lung disease (which is sometimes severe), pulmonary arterial hypertension, or primary cardiac damage, which represent the three commonest causes of mortality in SSc. Another type of involvement with poor prognosis, scleroderma renal crisis, is rare (less than 5% of cases). Cutaneous extension is also an important parameter, with the diffuse cutaneous forms having less favorable prognosis.

Published
2021
Full Text
View/download PDF

18. High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome

Author

Bubien, Virginie, Bonnet, Françoise, Brouste, Veronique, Hoppe, Stéphanie, Barouk-Simonet, Emmanuelle, David, Albert, Edery, Patrick, Bottani, Armand, Layet, Valérie, Caron, Olivier, Gilbert-Dussardier, Brigitte, Delnatte, Capucine, Dugast, Catherine, Fricker, Jean-Pierre, Bonneau, Dominique, Sevenet, Nicolas, Longy, Michel, Caux, Frédéric, Abramowicz, Marc, Bessis, Didier, Bieth, Eric, Bérard, Valérie Bonadonaon, Bonnetblanc, Jean-Marie, Demange, Liliane, Feillet, François, Frebourg, Thierry, Giraud, Sophie, Giurgea, Irina, Heron, Delphine, Holder, Muriel, Journel, Hubert, Julia, Sophie, Kacem, Maha, Lejeune, Sophie, Leprat, Frédéric, Leroux, Dominique, Lok, Catherine, Lortholary, Alain, Lyonnet, Stanislas, Margueritte, Geneviève, Mauillon, Jacques, Mazereeuw-Hautier, Juliette, Odent, Sylvie, Penet, Clotilde, Philippe, Anne, Plauchu, Henri, Plessismenceau, Ghislaine, Plouvieron, Emmanuel, Richard, Marie-Aleth, Saadi, Abdelkrim, Saurin, Jean-Christophe, Tinat, Julie, Vabres, Pierre, Van Maldergemteil, Lionel, Vennin, Philippe, and Weiller, Pierre-Jean

Published
2013
Full Text
View/download PDF

19. Prognostic Factors of Paraneoplastic Pemphigus

Author

Leger, Sandy, Picard, Damien, Ingen-Housz-Oro, Saskia, Arnault, Jean-Philippe, Aubin, François, Carsuzaa, Francis, Chaumentin, Gilles, Chevrant-Breton, Jacqueline, Chosidow, Olivier, Crickx, Béatrice, D’incan, Michel, Dandurand, Michel, Debarbieux, Stéphane, Delaporte, Emmanuel, Dereure, Olivier, Doutre, Marie-Sylvie, Guillet, Gérard, Jullien, Denis, Kupfer, Ingrid, Lacour, Jean-Philippe, Leonard, Fabienne, Lok, Catherine, Machet, Laurent, Martin, Ludovic, Paul, Carle, Pignon, Jean-Michel, Robert, Caroline, Thomas, Luc, Weiller, Pierre-Jean, Ferranti, Vincent, Gilbert, Danièle, Courville, Philippe, Houivet, Estelle, Benichou, Jacques, and Joly, Pascal

Published
2012
Full Text
View/download PDF

25. Prediction of Survival for Patients With Bullous Pemphigoid: A Prospective Study

Author

Joly, Pascal, Benichou, Jacques, Lok, Catherine, Hellot, Marie France, Saiag, Philippe, Tancrede-Bohin, Emmanuelle, Sassolas, Bruno, Labeille, Bruno, Doutre, Marie Sylvie, Gorin, Isabelle, Pauwels, Christine, Chosidow, Olivier, Caux, Frédéric, Estève, Eric, Dutronc, Yves, Sigal, Michèle, Prost, Catherine, Maillard, Hervé, Guillaume, Jean Claude, and Roujeau, Jean Claude

Published
2005

26. Bone Complications of Mastocytosis: A Link between Clinical and Biological Characteristics

Author

Guillaume, Nicolas, Desoutter, Judith, Chandesris, Olivia, Merlusca, Lavinia, Henry, Isabelle, Georgin-Lavialle, Sophie, Barete, Stéphane, Hirsch, Isabelle, Bouredji, Daoud, Royer, Bruno, Gruson, Bérengère, Lok, Catherine, Sevestre, Henri, Mentaverri, Romuald, Brazier, Michel, Meynier, Jonathan, Hermine, Olivier, Marolleau, Jean-Pierre, Kamel, Said, and Damaj, Gandhi

Published
2013
Full Text
View/download PDF

27. Prediction of Survival for Patients wiht Bullous Pemphigoid

Author

Pascal, Joly, Benichou, Jacques, Lok, Catherine, Hellot, Marie France, Saiag, Philippe, Tancrede-Bohin, Emmanuelle, Sassolas, Bruno, Labeille, Bruno, Doutre, Marie Sylvi, Gorin, Isabelle, Pauwel,Christine, Chosidow, Olivier, Caux, Frederic, Esteve, Eric, Dutronc, Yves, Sigal, Michele, Prost, Catherine, Maillard, Herve, Guillaume, Jean Claude, and Roujeau, Jean Claude

Subjects
Clobetasol -- Dosage and administration, Patients -- Prognosis, Bullous pemphigoid -- Research, Health
Published
2005

28. Brain magnetic resonance imaging in patients with Cowden syndrome

Author

Lok, Catherine, Viseux, Valerie, Avril, Marie Francoise, Richard, Marie Aleth, Gondry-Jouet, Catherine, Deramond, Herve, Desfossez-Tribout, Caroline, Courtade, Sandrine, Delaunay, Michele, Piette, Frederic, Legars, Daniel, Dreno, Brigitte, Saiag, Philippe, Longy, Michel, Lorette, Gerard, Laroche, Liliane, and Caux, Frederic

Subjects
Genetic disorders -- Diagnosis, Brain tumors -- Research, Anticonvulsants
Published
2005

32. Melanoma and Tumor Thickness: Challenges of Early Diagnosis

Author

Richard, Marie Aleth, Grob, Jean Jacques, Avril, Marie Francoise, Delaunay, Michele, Thirion, Xavier, Wolkenstein, Pierre, Souteyrand, Pierre, Dreno, Brigitte, Bonerandi, Jean Jacques, Dalac, Sophie, Machet, Laurent, Guillaume, Jean Claude, Chevrant-Breton, Jacqueline, Vilmer, Catherine, Aubin, Francois, Guillot, Bernard, Beylot-Barry, Marie, Lok, Catherine, Raison-Peyron, Nadia, and Chemaly, Philippe

Published
1999

38. Iatrogenic cutaneous graft versus host disease.

Author

Cohen-Sors, Raphaëlla, Arnault, Jean-Philippe, Attencourt, Christophe, Charbonnier, Amandine, Adas, Alanoud, Chaby, Guillaume, and Lok, Catherine

Subjects
GRAFT versus host disease, IATROGENIC diseases, ANTINEOPLASTIC agents, IMMUNOREGULATION, DERMATOLOGISTS
Abstract

A 65-year-old man with acute myeloid leukemia was treated by bone marrow allograft and developed classic systemic chronic graft versus host disease with hepatic, rheumatologic, ophthalmic, and mucocutaneous involvement. He received systemic corticosteroid, ruxolitinib, and extracorporeal photopheresis, which resulted in complete remission. During follow-up the patient presented with viral cutaneous warts on his neck and submandibular area. After various subsequent topical treatments, he developed localized cutaneous GVHD without any general GVHD reactivation symptoms. To the best of our knowledge, there has been no description in the literature of graft versus host disease developing after local immunomodulatory or cytotoxic treatments. Topical immune-stimulating therapies are commonly used by dermatologists for superficial skin cancers and some viral skin lesions in high-risk populations such as organ transplant patients. Practitioners should be made aware of a possible localized cutaneous GVHD reactivation induced after local therapy. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

39. An Erythemato-papular and Nodular Lesion on the Earlobe.

Author

Halle, Aurélie, Lombart, Florian, Chaby, Guillaume, Bendamman, Mickaël, Lok, Catherine, and Hamdad, Farida

Subjects
DRUG therapy for tuberculosis, TUBERCULOSIS diagnosis, ANTITUBERCULAR agents, BIOPSY, DIFFERENTIAL diagnosis, EXTERNAL ear, EDEMA, ERYTHEMA, MYCOBACTERIUM tuberculosis, SKIN, TUBERCULOSIS, TREATMENT effectiveness, SYMPTOMS
Abstract

The article describes the case of an erythemato-papular and nodular lesion on the earlobe in a 78-year-old woman in France in June 2012. Highlights include a dense infiltrate with lymphocytes and plasma cells shown by a biopsy of the lesioned skin, computed tomography scan of the thorax, abdomen, and pelvis, and serologic tests for human immunodeficiency virus and syphilis.

Published
2020
Full Text
View/download PDF

40. Asymmetric periflexural exanthem of childhood and influenza virus infection.

Author

Cohen-Sors, Raphaella, Dadban, Ali, Perzon, Juliette, and Lok, Catherine

Subjects
INFLUENZA viruses, EXANTHEMA, ETIOLOGY of diseases, SKIN examination, PATHOLOGICAL physiology
Abstract

Assymetric periflexural exanthem of childhood (APEC) is a self-limited disease characterized by unilateral exanthem. the etiology is unknown, but a viral agent is suspected. Most often there is no formal proof of an associated viral etiology, but several associations between APEC and some viruses have beed described. We report a 2-year-old girl with APEC assocoatied with the influenza A. This case allows us to provide an additional argument on a probable viral etiology of APEC and possible etiologic role of influenza A. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

48. Livedoid Vasculopathy: A French Observational Study Including Therapeutic Options.

Author

GARDETTE, Emma, FRANCES, Camille, BARETE, Stéphane, MOGUELET, Philippe, BOUAZIZ, Jean David, LIPSKER, Dan, DEREURE, Olivier, BESSIS, Didier, LE PELLETIER, François, LOK, Catherine, MAISONOBE, Thierry, and CONARD, Jacqueline

Subjects
SKIN diseases, HYPERCOAGULATION disorders, ELECTROMYOGRAPHY, NEUROPATHY, HEPARIN, ANTICOAGULANTS, IMMUNOGLOBULINS
Abstract

Livedoid vasculopathy is a rare thrombotic cutaneous disease. This observational study aimed to assess the clinical and biological features of livedoid vasculopathy and the efficacy of treatments. Patients enrolled had typical livedoid vasculopathy both clinically and histologically. Investigation of thrombophilia was performed. Electromyography was undertaken in the presence of symptoms suggesting peripheral neuropathy. Eighteen women and 8 men were included, with a mean age of 35.5 years at onset. Twenty patients had at least one thrombophilia factor. Ten patients had a peripheral neuropathy with 2 of these patients demonstrating a specific thrombo-occlusive vasculopathy on muscle biopsy. Anticoagulation with low molecular weight heparin was the most prescribed therapy and was associated with the best outcome (effective in 14 patients). Eight patients had severe disease refractory to anticoagulation and required intravenous immunoglobulins, producing a good response in 6 patients. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

49. Lower-limb Ulcers in Systemic Sclerosis: A Multicentre Retrospective Case-control Study.

Author

BOHELAY, Gérôme, BLAISE, Sophie, LEVY, Pierre, CLAEYS, Antoine, BAUDOT, Nathalie, CUNY, Jean-Francois, MAILLARD, Hervé, GRANEL-BROCARD, Florence, BOYÉ, Thierry, LOK, Catherine, BÉNÉTON, Nathalie, FRANCÈS, Camille, and SENET, Patricia

Subjects
LEG, SYSTEMIC scleroderma, COLLAGEN diseases, CREST syndrome, SKIN diseases, ULCERS, EPIDEMIOLOGY
Abstract

Lower-limb ulcers in systemic sclerosis patients are rarely reported. The aim of this study was to describe the main causes and outcomes of lower-limb ulcers in systemic sclerosis patients and to assess factors associated with ischaemic causes (arterial disease and/or microvascular impairment). A retrospective, multicentre, case-control study was conducted in 2013 and 2014, including 45 systemic sclerosis patients presenting lower-limb ulcers between 2008 and 2013. The estimated prevalence of lower-limb ulcers among systemic sclerosis patients was 12.8%. Ulcers were related to venous insufficiency in 22 cases (49%), ischaemic causes in 21 (47%) and other causes in 2 (4%). Complete healing was observed in 60% of cases in a mean time of 10.3 months; 59% relapsed during a mean followup of 22 months. Ischaemic lower-limb ulcer outcomes were poor, with a 28.6% amputation rate. Logisticregression multivariate analyses between ischaemic lower-limb ulcer cases and matched systemic sclerosis-controls identified past or concomitant digital ulcer and cutaneous sclerosis of the feet as independent risk factors associated with ischaemic lower-limb ulcers. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

50. Atypical cutaneous hyperpigmentation after multiple chemotherapy agents.

Author

Dessirier, Fanny, Arnault, Jean-Philippe, Farre, Isabelle, Poulet, Claire, Chaby, Guillaume, Dairi, Motaz, and Lok, Catherine

Subjects
HYPERPIGMENTATION, CISPLATIN, IMMUNOHISTOCHEMISTRY
Abstract

We report a case of cutaneous hyperpigmentation after injection of cisplatin, carboplatin, pemetrexed, and bevacizumab in patient treated for stage IV lung adenocarcinoma. After the 5th cycle, facial and palmoplantar hyperpigmented macules appeared. The histological examination showed a pigmentary incontinence. The appearance of pigmented palmar macules have been described in association with different chemotherapeutic agents, but to the best of our knowledge an association with the drugs that were administered to our patient have never been described. Photoprotected areas were affected as well as photoexposed zones, an uncommon finding. Post chemotherapy histological and immunohistochemistry studies of such hyperpigmentation have rarely been performed, but in the few studies found, the number of melanocytes was stable. However excessive melanin production in the basal keratinocytes was frequently observed. The pigmentary incontinence could be secondary to an accumulation of drugs in the affected areas by sweat excretion and direct cytotoxicity on the melanocytes. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results